Vertex Pharmaceuticals VRTX
NASDAQ VRTX
$499.74 -9.01 (-1.77%)
At close: Oct 16, 2026 · 4:00 PM EDT

Vertex Pharmaceuticals (VRTX) Net Income towards Common Stockholders (2009 - 2026)

Updated

Vertex Pharmaceuticals (VRTX) recorded Net Income towards Common Stockholders of $1.1 billion in Q2 2026, up 6.5% from $1.03 billion a year earlier and up 6.6% from the prior quarter.

Analysis

Vertex Pharmaceuticals (VRTX) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

On a TTM basis, Vertex Pharmaceuticals' Net Income towards Common Stockholders came in at $4.41 billion as of Jun 30, 2026, up 21.1% year-over-year; for FY2025, it was $3.95 billion.

  • Annual Net Income towards Common Stockholders has a five-year compound annual growth rate of 7.8% (FY2020 to FY2025).
  • Across earlier years, Net Income towards Common Stockholders came in at -$535.6 million in FY2024, $3.62 billion in FY2023 (+9.0%), $3.32 billion in FY2022 (+41.8%) and $2.34 billion in FY2021 (-13.6%).
  • Quarterly Net Income towards Common Stockholders has ranged from -$3.59 billion in Q2 2024 to $1.19 billion in Q4 2025 over the past five years.
  • On a year-over-year basis, Net Income towards Common Stockholders has increased for four consecutive quarters, with growth averaging 7.7% over the last seven quarters.
  • Peak year-over-year performance for Net Income towards Common Stockholders in the last five years was growth of 59.6% in Q1 2026, against a decline of 41.2% in Q1 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at $1.03 billion (Q1 2026), $1.19 billion (Q4 2025) and $1.08 billion (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn 5.53 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn 3.61 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn 2.51 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn -10.50 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn -248.00 Mn
10 Vertex Pharmaceuticals 126.70 Bn 98.70 Bn 2.84 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.10 Bn
Mar 31, 2026 1.03 Bn
Dec 31, 2025 1.19 Bn
Sep 30, 2025 1.08 Bn
Jun 30, 2025 1.03 Bn
Mar 31, 2025 646.30 Mn
Dec 31, 2024 913.00 Mn
Sep 30, 2024 1.05 Bn
Jun 30, 2024 -3.59 Bn
Mar 31, 2024 1.10 Bn
Dec 31, 2023 968.80 Mn
Sep 30, 2023 1.04 Bn
Jun 30, 2023 915.70 Mn
Mar 31, 2023 699.80 Mn
Dec 31, 2022 818.90 Mn
Sep 30, 2022 930.50 Mn
Jun 30, 2022 810.50 Mn
Mar 31, 2022 762.10 Mn
Dec 31, 2021 770.10 Mn
Sep 30, 2021 851.90 Mn
API Access

Vertex Pharmaceuticals Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=VRTX&period=max&api_key=YOUR_API_KEY